OMEGA-3 EPA/DHA CONTRIBUTE TO
MAINTAINING NORMAL HEART FUNCTION*
OMEGA-3 EPA/DHA CONTRIBUTE TO
Daily dietary supplement containing HIGH CONCENTRATION omega-3:
- EPASCC 325 mg
- Rapid bioavailability capsules
Om3gafortSCC uses HIGH CONCENTRATION Omega-3 polyunsaturated fatty acids EPA/DHA, EFFICACY, PURITY and SAFETY obtained with an ENVIRONMENTALLY FRIENDLY technology known as Supercritical Concentration (SCC).
Om3gafortSCC EPASCC uses LiqFillCapsTM hard capsules that facilitate better absorption of EPA in the body.
LiqFillCapsTM are an innovative technological concept that provide effective solutions for many of the challenges faced by the pharmaceutical and neutraceutical industry. In particular those related to the low solubility of bioactive ingredients and agents, thus obtaining increased oral bioavailability and absorption.
Daily dose: 2 capsules. % DV based on daily dose.
|1 capsule||2 capsule||% DV*|
|Energy value in kcal||4,8 kcal||9,6 kcal||**|
|Energy value in kJ||20,0 kJ||40,0 kJ||**|
|Protein||78 mg||156 mg||**|
|Carbohydrates||24 mg||48 mg||**|
|Total Fat / Lipids||486 mg||972 mg||**|
|Polyunsaturated fat||470 mg||940 mg||**|
|Omega-3 fatty acids#||425 mg||850 mg||**|
|EPA (eicosapentaenoic acid)||325 mg||650 mg||**|
|DHA (docosahexaenoic acid)||50 mg||100 mg||**|
*Recommended daily amount as per Directive 2008/100/CE of 28 October 2008.
**Daily value not established.
#Guaranteed minimum quantity of the active ingredient expressed in mg. Percentages calculated on the basis of the minimum quantity expressed in mg are subject to variation.
Fish Oil: (minimum 65% EPA, minimum 10% DHA), Gelatin, Emulsifier: Soya Lecithin, Antioxidants: natural mixed tocopherols, Color Additives (E124).
Greater concentration, greater efficacy
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar 31;369(9567):1090-8.
- Chan EJ, Cho L. What can we expect from omega-3 fatty acids? Cleve Clin J Med. 2009 Apr;76(4):245-51.
High blood pressure (Hypertension):
- Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. J Hum Hypertens. 2005 Dec;19 Suppl 3:S25-33.
Triglycerides and HDL
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40. Epub 2008 Jun 19.
- von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag. 2006;2(3):251-62.
LiqFillCapsTM are an innovative technological concept that provides an efficient solution to the many challenges the pharmaceutical and nutraceutical industries face, in particular those due to the low solubility of active ingredients and bioactive agents, thereby helping to achieve an increase in both oral bioavailability and absorption.